GI Oncology Now | GI Oncology Now

CheckMate 577: Adjuvant Nivolumab Plus Neoadjuvant Chemoradiotherapy for Esophageal and Gastroesophageal Cancer

Ronan Kelly, MD, Baylor University Medical Center, discusses the first overall survival results from CheckMate 577, which examined the use of adjuvant nivo in patients with resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy.

Dr. Kelly explains how these OS results compare to the DFS benefit seen with adjuvant nivo earlier in the study, and if adjuvant immunotherapy should be utilized in patients with pathologic disease post-CRT.

Latest News

Disitamab Vedotin Regimens Effective in HER2+ Gastric Cancer

Lauren Dembeck, PhDEsophageal Cancer | June 9, 2025

In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.

DYNAMIC-III's ctDNA-Positive Cohort: Utilizing ctDNA to Guide Adjuvant Chemotherapy Escalation in Patients With Stage III Colon Cancer

Jeanne Tie, MD, MBChBASCO 2025 | June 6, 2025

Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.

MATTERHORN: Practice-Changing Treatment Paradigm for Resectable G/GEJ Cancers

Zev Wainberg, MD, MScGastric Cancer | June 6, 2025

Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.

The Rapidly Evolving Treatment Landscape of Gastroesophageal Cancers: Significant Progress, But a Long Way to Go

Jessica Nye, PhDEsophageal Cancer | June 6, 2025

We recently spoke with expert clinicians about the rapidly changing treatment landscape in upper gastrointestinal cancers.

ATOMIC: Adjuvant Chemo Alone, With Atezo for Patients With Stage III dMMR Colon Cancer

Christopher Lieu, MDColorectal Cancer | June 5, 2025

Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.

BREAKWATER Trial Shows Practice-Changing Survival Benefit in BRAF V600E–Mutant mCRC

Lauren Dembeck, PhDColorectal Cancer | June 5, 2025

The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.

ATOMIC: Atezolizumab Plus Chemotherapy as New SOC in Stage III dMMR Colon Cancer

Lauren Dembeck, PhDColorectal Cancer | June 5, 2025

The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.

Bridging GI Oncology Care and Compassion: Dr. Joseph McCollom on Hope, Healing, and Human Connection

Joseph McCollom, DOPancreatic Cancer | June 4, 2025

Dr. Joseph McCollom discusses his path to specialization in GI cancers and the pivotal role of palliative care in oncology.

HERIZON-BTC-01 vs a Real-World Control Arm: Comparing Zanidatamab With Chemotherapy for Biliary Tract Cancer

Richard Kim, MDBile Duct Cancer | June 3, 2025

Dr. Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ BTC.

LEAP-002 Long-Term Follow-Up: Further Exploring Lenvatinib Plus Pembrolizumab for Liver Cancer

Richard S. Finn, MDLiver Cancer | June 3, 2025

Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.

Editorial Advisory Board

Christopher Lieu, MDEditor | Co-Director of Gastrointestinal Medical Oncology at University of Colorado Medicine

Benjamin Weinberg, MD, FACPEditor | Associate Professor of Medicine at Lombardi Comprehensive Cancer Center

Zev Wainberg, MD, MScEditor | Co-Director of Gastrointestinal Oncology at the University of California, Los Angeles

Roundtable Discussions

Conference Coverage

ASCO 2025

The latest news and research updates in GI cancer treatment from the ASCO 2025 Annual Meeting.

ASCO GI Symposium 2025

GI Oncology Now reviews education from ASCO GI 2025, featuring the latest advances in the field of GI cancer research.

ASCO GI Symposium 2025: Focus on Liver Cancer

Coverage of the 2025 ASCO GI Symposium, with a focus on liver cancer

ASCO GI Symposium 2024

GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.

ASCO 2024: GI Oncology Now

The latest news and research updates in GI cancer treatment from the ASCO 2024 Annual Meeting

ESMO 2024: GI Oncology Now

The latest news and research updates in GI cancer treatment from the ESMO Congress 2024

Latest News

Roundtable Discussions

Conference Coverage

Video Insights

Knowledge Hubs

Bile Duct

Colorectal

Gastric

Esophageal

GEP-NETs

GIST

Liver

Pancreatic

Bile Duct

Colorectal

Gastric

Esophageal